CD19 and cancer: Figures 4(a) and 4(b) show that CD19-NK-92 cells significantly improved the NK killing in Raji and REH cells when compared to their respective WT-NK-92 control, while having a minimal effect on K562, H929, and RPMI-8226 cells, indicating its specificity toward target cancer cells presenting CD19 antigen.